Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
TRPV2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPV2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
TRPM8 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPM8, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Chronic Kidney Disease Indication Strategy Report 2026: SGLT2, MR, Trials and Deals
17 July 2026
Chronic Kidney Disease Indication Strategy Report 2026: SGLT2, MR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Atopic Dermatitis Indication Strategy Report 2026: IL-4Rα, IL-13, Trials and Deals
17 July 2026
Atopic Dermatitis Indication Strategy Report 2026: IL-4Rα, IL-13, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Lupus Nephritis Indication Strategy Report 2026: BAFF, CD20, Trials and Deals
17 July 2026
Lupus Nephritis Indication Strategy Report 2026: BAFF, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
8 min read
TRPM7 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPM7, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Multiple Myeloma Indication Strategy Report 2026: BCMA, GPRC5D, Trials and Deal Outlook
17 July 2026
A 2026 multiple myeloma strategy report covering disease burden, BCMA and GPRC5D biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal
17 July 2026
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Non-Small Cell Lung Cancer Indication Strategy Report 2026: EGFR, KRAS, Trials and Deal Outlook
17 July 2026
A 2026 NSCLC indication strategy report covering epidemiology, EGFR and KRAS biology, Phase 3 competition, deal activity and R&D positioning.
8 min read
TRPM4 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for TRPM4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Inflammatory Bowel Disease Indication Strategy Report 2026: Unmet Need, Competition, Targets and Market Attractiveness
17 July 2026
Inflammatory Bowel Disease 2026 strategy: unmet need, clinical competition, target mechanisms and 2023–2026 deal signals from PatSnap MCP workflows.
Latest Hotspot
8 min read
MASH Indication Strategy Report 2026: Epidemiology, Target Biology, Clinical Competition and Deal Outlook
17 July 2026
A 2026 MASH indication strategy report covering disease burden, THR-β and FGF21 biology, clinical competition, deal activity and R&D positioning.